Athira Pharma, Inc.
ATHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $479 |
| Gross Profit | $0 | $0 | $0 | -$479 |
| % Margin | – | – | – | – |
| R&D Expenses | $70,682 | $93,790 | $61,464 | $42,794 |
| G&A Expenses | $26,093 | $33,304 | $32,552 | $21,228 |
| SG&A Expenses | $26,093 | $33,304 | $32,552 | $21,228 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,127 | -$1,628 | $10,000 | -$479 |
| Operating Expenses | $100,902 | $125,466 | $104,016 | $63,543 |
| Operating Income | -$100,902 | -$125,466 | -$104,016 | -$64,022 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,962 | $7,794 | $8,377 | $9,169 |
| Pre-Tax Income | -$96,940 | -$117,672 | -$95,639 | -$54,853 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$96,940 | -$117,672 | -$95,639 | -$54,853 |
| % Margin | – | – | – | – |
| EPS | -25.2 | -30.9 | -25.3 | -14.9 |
| % Growth | 18.4% | -22.1% | -69.8% | – |
| EPS Diluted | -25.2 | -30.9 | -25.3 | -14.9 |
| Weighted Avg Shares Out | 3,848 | 3,802 | 3,773 | 3,692 |
| Weighted Avg Shares Out Dil | 3,848 | 3,802 | 3,773 | 3,692 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,962 | $7,637 | $3,216 | $337 |
| Interest Expense | $0 | $0 | $24,316 | $3 |
| Depreciation & Amortization | $970 | $969 | $845 | $479 |
| EBITDA | -$95,805 | -$125,968 | -$88,010 | -$54,371 |
| % Margin | – | – | – | – |